Home / Conditions / Lymph Nodes
Lymph Nodes: when insurers say no, reviewers often say yes
In 56 published external-review decisions involving lymph nodes, independent physician reviewers overturned the insurer’s denial 44.6% of the time.
Published decisions
56
2001–2026
Overturned
44.6%
25 denials reversed
Most-fought treatments for lymph nodes
What insurers denied — and how those fights ended.
| Category | Decisions | Overturned |
|---|---|---|
| PET Scan | 11 | 54.5% |
| Chemotherapy | 5 | 40% |
| Investigational Tx | 4 | 0% |
| Radiation Therapy | 3 | 33.3% |
| Radiation Oncology | 3 | 66.7% |
What the insurer actually argued
Denials fall into different categories, and they don’t succeed equally — so the reason on your letter changes how you should answer it.
| Reason given | Decisions | Overturned |
|---|---|---|
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 31 | 41.9% |
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 25 | 48% |
Typical time to a decision
13 days
Most land between 7 and 21 days
Handled as urgent
48.2%
Expedited when a delay would cause harm
Recent direction
Rising
28.6% → 40% overturned, last three years
What the reviewers wrote
Excerpts from the independent reviewers’ published findings — the actual reasoning, quoted, not summarised.
Where the denial was overturned
Physician 1: The patient is a 42-year-old male who had a right orchiectomy in August 2004 for seminoma. A 1.4cm retroperitoneal lymph node was identified on a follow-up CT scan. MRI of the abdomen in March 2006 showed increased activity in the retroperitoneal lymph node and in the right axilla. The patient received radiation therapy to his periaortic and pelvic lymph nodes. No abnormality was identified in the right axilla on the CT scan. A follow-up PET scan has been ordered to assess the activity in the axilla. The Health Plan has denied coverage for the requested PET scan.Prior Centers for Medicare and Medicaid Services (CMS) reimbursement standards did not include testicular cancer as an indication for PET scan.
Physician 1: The patient is a 42-year-old male who was diagnosed with T2 N0 M0 seminoma of the testicle on August 2004. He was treated with surgery alone, followed by surveillance for recurrence. In October 2005 a CAT scan identified a new 1.4 cm lymph node in the retroperitoneum. A follow-up MRI in March 2006 showed a slight enlargement of the node to 1.6 cm and a new 1.8 cm lesion in the L2 vertebral body. Neither of the lesions is definitively representative of recurrent cancer. The patient’s provider requested authorization for a PET scan to further analyze the clinical situation. The Health Plan denied authorization citing the investigational nature of the procedure in this clinical context.PET scans are a very different kind of scan than MRI or CAT scan.
Where the denial was upheld
Worth reading too — these show what an appeal has to overcome.
Nature of Statutory Criteria/Case Summary: an enrollee has requested authorization and coverage for an increase of hydrocodone and morphine. Findings: The physician reviewer found that dose escalation is not a long term plan but a short term plan for the treatment of tolerance. The stepwise World Health Organization (WHO) ladder for pain relief is considered the reasonable approach to pain control in the palliative setting. However, in the documentation available for review, no objective treatment goals for pain and function were noted for the requested medication dosage increase. The Centers for Disease Control and Prevention (CDC) states that when starting opioid therapy for chronic pain, clinicians should prescribe immediate-release opioids instead of extended-release/long-acting (ER/LA) opioids.
Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for air ambulance service provided on 12/27/17. The Health Plan has denied this request indicating that the requested service was not medically necessary for treatment of the enrollees epilepsy.At issue in this case is whether the requested air ambulance service was medically necessary for treatment of the enrollees medical condition.In most cases, air ambulance transport is reserved for use in emergent situations in which ground transport is not feasible or readily available. Such situations from the neurology perspective include (but are not limited to), intracranial hemorrhages, strokes requiring endovascular therapy or other conditions requiring acute surgical intervention.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California outcomes — every state runs an equivalent external review, but the rates here are California’s. Excerpts are quoted verbatim from the public record and describe this condition generally, not any individual case.
How to use this in your appeal
These outcomes come from California’s external review program — an independent physician panel whose decision binds the insurer. Every state has an equivalent, and internal appeals succeed even more often. If your care for lymph nodes was denied, the published record says the denial is worth fighting.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · DERIVED AGGREGATE STATISTICS ONLY · METHODOLOGY
Not legal or medical advice. Coverage Rights is a self-help tool that helps you prepare your own appeal. For advice about your specific situation, talk to a licensed attorney or your doctor.